Table 2.

Inflammatory bowel disease-specific medication use in the six months prior to initial stage of surgery

	Patients without pouchitis n=287		Patients with pouchitis n=260		p-value
	n	%	n	%
Mesalamine	107	37	141	54	<0.001
Sulfasalazine	11	4	9	3	0.817
Balsalazide	27	9	25	10	0.934
Immunomodulator (azathiopurine, mercaptopurine, or methotrexate)	58	20	66	25	0.149
Tacrolimus	4	1	3	1	0.803
Cyclosporine	2	1	1	0	0.664
Anti-TNF therapy	68	24	92	35	0.003
Prednisone	133	46	144	55	0.035
Budesonide (MMX and enteral release)	13	5	21	8	0.086

Anti-tumor necrosis factor alpha (anti-TNF); multimatrix (MMX)